GLP-1 receptor agonists and their role in managing type 2 diabetes.
Br J Community Nurs · 2024
Last updated 2026-05-28Type 2 diabetes affects about 5 million people in the UK, often linked to obesity. While lifestyle changes like diet and weight loss can help, medication is sometimes needed to manage the condition and reduce complications. This article explains how GLP-1 receptor agonists, a type of medication, can be used in treating type 2 diabetes.
AI summary of the abstract below.
| Journal | Br J Community Nurs, 2024 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Until recently the focus in diabetes care was on managing blood glucose - a glucocentric view. This is changing to a more holistic model aimed at prevention, treatment and management through lifestyle interventions as well as medication. An estimated 5 million people in the UK are living with diabetes, most have type 2 diabetes which is associated with obesity. Type 2 diabetes can be prevented, treated with diet and weight loss, or managed with medication. The number of people with diabetes has reached epidemic proportions. To manage diabetes well and reduce complications of poorly managed diabetes, management of the condition can no longer be restricted to endocrinologists and diabetes specialist nurses. This article provides guidance on how glucagon-like peptide-1 receptor agonists can be used in the management of type 2 diabetes.
Verbatim abstract via PubMed 39072740 ↗